A new dual sodium-glucose cotransporter 1 and 2 (SGLT1/2) inhibitor called sotagliflozin has showed promise in the treatment of chronic kidney, diabetes and heart disease. Diabetes mellitus (DM) is a condition that is closely related to chronic kidney disease (CKD) and DM is also a major risk factor for the onset and progression of CKD. The benefits of sotagliflozin for Type 1 diabetes may also outweigh the risk of diabetic ketoacidosis as a whole. In the current analysis, the risk of cardiovascular disease and renal failure in people with Type one diabetes is estimated. It is now being determined how sotagliflozin affects cardiovascular outcomes through its clinical trials. In addition to lowering blood sugar, sotagliflozin also reduced the risk of cardiovascular events with certain pharmacological and pharmacokinetic way. Resent clinical study supports the data where sotagliflozin affects cardiovascular events in patients with type two diabetes who had worsening heart failure conditions. This extensive study focuses on the pharmacological aspects of sotagliflozin on glycaemic management, renal outcomes, cardiovascular outcomes and adverse events in order to assess the sotagliflozin mode of action and pharmacological study.
Loading....